Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (28688)	4/13/1999 7:55:00 PM
From: Henry Niman	Respond to of 32384

Actually, LGND has issued press releases on quite a few studies using Targretin alone or in combination with Tamoxifen and all of these studies have been on rats. The press release did mention that the initial data was presented to the NSABP and I had commented back then on the significance of the rat model as well as the significance of the presentation to the NSABP. A quick review on LGND's press releases: businesswire.com or the last one on Targretin and Breast Cancer businesswire.com should not leave any doubt that the current press release was on rats, and most of the data was presented last year in the initial report. Sometimes its useful to read these reports before you invest. You might also note that the initial rat data was presented at the Bear Stearns conference on Sept 12, 1996: Subject 8060